News & Events

Press Releases

November 05, 2020
Nimbus Therapeutics to Present Updated Preclinical Data From HPK1 Inhibitor Program in Scientific Seminar
October 22, 2020
Nimbus Therapeutics to Present New Data on Novel HPK1 Inhibitors at Upcoming Scientific Conferences
October 19, 2020
Nimbus Therapeutics Appoints Erin Cowhig as Chief People Officer
October 14, 2020
Nimbus Therapeutics Announces $60 Million Private Financing From New Investors to Advance Expanded Pipeline
September 28, 2020
Nimbus Therapeutics Appoints Abbas Kazimi as Chief Business Officer
September 01, 2020
Nimbus Therapeutics Appoints Veteran Pharmaceutical Chemist Scott Edmondson, Ph.D., as Senior Vice President, Head of Chemistry
June 22, 2020
Nimbus Therapeutics Presents Data on Novel HPK1 Inhibitor, Demonstrating Robust Inhibition of Tumor Growth In Vivo
June 18, 2020
Nimbus Therapeutics to Host Scientific Seminar on Promising Preclinical Data from HPK1 Program
June 08, 2020
Nimbus Therapeutics Announces Expansion of its Drug Discovery Pipeline Across Oncology, Immunology and Metabolism
May 29, 2020
Nimbus Therapeutics Announces Promotion of Alan Collis, Ph.D., to Senior Vice President, Preclinical Development
May 15, 2020
Nimbus Therapeutics Announces Identification of a Potent, Selective HPK1 Inhibitor with Robust In Vivo Activity
December 17, 2019
Nimbus Therapeutics Appoints Chief Medical Officer Annie C. Chen, M.D., MPH, to President of the Company’s Tyk2 Subsidiary
September 19, 2019
Nimbus Therapeutics Appoints Accomplished Biologist and Research Director Christine Loh, Ph.D., to Lead Biology Team
July 09, 2019
Nimbus Therapeutics and Celgene Expand Alliance to Immunotherapy in Oncology
April 03, 2019
Nimbus Therapeutics Publishes First-Ever High-Resolution Structure of ATP-Citrate Lyase
March 20, 2019
Nimbus Therapeutics Grows Scientific Team, Adding Leaders in Biology and Preclinical Development
February 14, 2019
Nimbus Therapeutics Appoints Peter Tummino, Ph.D., as Chief Scientific Officer
January 03, 2019
Nimbus Therapeutics Strengthens Leadership Team
October 04, 2018
Nimbus Therapeutics Names Jeb Keiper as President and Chief Executive Officer
July 09, 2018
Nimbus Therapeutics Names Adrian Ray, Ph.D., as Senior Vice President of Discovery Biology
June 05, 2018
Nimbus Therapeutics Announces $65 Million in New Financing to Accelerate Pipeline Progress and Expand Discovery Efforts
March 08, 2018
Nimbus Therapeutics Announces Departure of Chief Scientific Officer Rosana Kapeller, M.D., Ph.D.
October 03, 2017
Nimbus Therapeutics and Celgene Enter Long-Term Strategic Immunology Alliance to Develop Programs for Patients with Autoimmune Disorders
April 05, 2017
Nimbus Therapeutics Enters into Strategic Partnership with Charles River Laboratories to Advance New Therapeutics Programs
January 05, 2017
Nimbus Therapeutics Appoints Mark Ashwell, Ph.D., as Head of Chemistry
November 01, 2016
Nimbus Therapeutics announces $200 million milestone payment from Gilead Sciences for Allosteric ACC Inhibitor program in Non-alcoholic steatohepatitis (NASH)
September 19, 2016
Nimbus Therapeutics’ ACC Inhibitor Nd-646 Featured in Nature Medicine
May 17, 2016
Nimbus Therapeutics Announces Closing of Gilead Sciences’ Acquisition of Nimbus Apollo, Inc., and Its Acetyl-Coa Carboxylase (ACC) Inhibitor Program
April 04, 2016
Gilead Sciences Announces Acquisition of Nimbus Therapeutics’ Acetyl-Coa Carboxylase (ACC) Program for Nash and Other Liver Diseases
February 02, 2016
Nimbus Therapeutics Granted Fast Track Designation for Its Allosteric ACC Inhibitor, Ndi-010976, for the Treatment of Nash
December 22, 2015
Nimbus Therapeutics Achieves Second Milestone in Research Collaboration with Monsanto
November 10, 2015
Nimbus Therapeutics Announces Progress On Key Therapeutic Programs
October 20, 2015
Nimbus Therapeutics Announces Global License Agreement with Genentech
September 09, 2015
Nimbus Therapeutics Appoints Annie C Chen, M.D., M.P.H., as Chief Medical Officer
July 07, 2015
Nimbus Therapeutics Appoints Mark Iwicki and George Vlasuk to Its Board of Directors
April 21, 2015
Nimbus Therapeutics Announces Initiation of Clinical Studies For ACC Inhibitor
March 18, 2015
Nimbus Therapeutics Raises $43 Million in Series B Financing
December 10, 2014
First Milestone Reached in Monsanto Collaboration
November 04, 2014
Jeb Keiper, M.S., M.B.A., Appointed Nimbus Discovery CBO
September 30, 2014
Donald Nicholson, Ph.D., Appointed Nimbus Discovery CEO
April 01, 2014
Selective ACC Inhibitors Dramatically Impact Tumor Growth
December 09, 2013
IRAK4 Inhibitor Demonstrates Synergistic Effects with Kinase Inhibitors
November 04, 2013
ACC Inhibitors for Potential Diabetes, Nash and Liver Cancer Treatment
June 27, 2013
Nimbus Discovery and Monsanto Announce Collaboration
June 22, 2013
Preclinical Proof of Concept Data on Novel ACC Allosteric Inhibitor Nd-630
May 08, 2013
Nimbus and Shire To Co-Develop Therapies for Rare Diseases
February 06, 2013
Wes Westlin Appointed Head of Preclinical Research and Early Development
January 28, 2013
Inhibitors for Treatment of Metabolic Syndrome and Diabetes
December 09, 2012
Irak4 Inhibitors Synergize with Ibrutinib
November 12, 2012
Irak4 Inhibitors for the Treatment of Rheumatic Diseases
November 08, 2012
Nimbus-Proteros X-Ray Crystallography Partnership
November 01, 2012
Daniel Lynch Joins Nimbus As Executive Chairman
April 20, 2012
2012 Women to Watch: Rosana Kapeller
April 19, 2012
Cycle Computing Ramps Global 50,000-Core Cluster For Schrodinger Molecular Research
June 28, 2011
Nimbus Discovery Secures $24mm Series A Financing
March 10, 2011
Nimbus Discovery Unveils First of Its Kind Drug Discovery Paradigm; Announces Seed Round Co-Led By Bill Gates
Abbas Kazimi Interview – Biotech 2050 Podcast
July 22, 2020
Read more
Abbas Kazimi Interview – Biotech 2050 Podcast
July 22, 2020
Read more
Core (Values) Workout
March 05, 2020

Like many middle-aged weekend warriors, I’ve been recently sidelined by injury simply through doing what I’ve regularly done: run. Injury stopped me from running last fall and I’ve since seen orthopods and running experts galore.

But it’s been the physical therapists who’ve really laid the hammer home: “Jeb, you need to work on your core.”

Read more
Dealmarking in a time of coronavirus
July 15, 2020
Read more
Setting The Pace In The Race To Treat NASH
December 09, 2015
Read more

Upcoming Events

Our CEO Jeb Keiper will be joining a Fireside Chat / Panel Discussion at the Evercore ISI HealthCONx Virtual Conference at 12:10pm ET on December 2nd.

December 2

Our Senior Vice President, Head of Biology Christine Loh, Ph.D., will be speaking at an upcoming Wuxi webinar on December 9th.

December 9